Strategies and outcomes of cardiac surgery in Jehovah's witnesses

Journal of Cardiac Surgery

Volumn 26, Issue 2, 2011, Pages 135-143

  Moraca, Robert J ^a   Wanamaker, Kelly M ^a   Bailey, Stephen H ^a   McGregor, Walter E ^a   Benckart, Daniel H ^a   Maher, Thomas D ^a   Magovern Jr , George J ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; FERROUS SULFATE; HEMOGLOBIN; HEPARIN; PROTAMINE SULFATE; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ANESTHESIA INDUCTION; ANTICOAGULANT THERAPY; ARTICLE; ASCENDING AORTA SURGERY; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BLOOD TRANSFUSION; BODY SURFACE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RISK SCORE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; EMERGENCY SURGERY; HEALTH BELIEF; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HEART VALVE REPLACEMENT; HEMOCONCENTRATION; HEMODILUTION; HEPARINIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; INTRAOPERATIVE PERIOD; IRON THERAPY; JEHOVAH'S WITNESS; KIDNEY FAILURE; LENGTH OF STAY; LOADING DRUG DOSE; MEDICAL RECORD REVIEW; MEDLINE; MORTALITY; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PROPHYLAXIS; REOPERATION; RISK ASSESSMENT; SURGICAL RISK; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TRANSFUSION RISK UNDERSTANDING SCORING TOOL; TREATMENT OUTCOME; VALVULOPLASTY;

AGED; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; JEHOVAH'S WITNESSES; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 79952718973     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2011.01215.x     Document Type: Article

References (39)

1. Watchtower Bible and Tract Society. Statistics [Internet] Available from http://www.watchtower.org/e/ statistics/worldwidereport.htm [cited January 19, 2010].
2. Cooley DA, Crawford FS, Howell JF, et al: Open heart surgery in Jehovah's Witnesses. Am J Cardiol 1964;13:779-781.
3. Rosengart T, Helm R, DeBois WJ, et al: Open heart operations without transfusing using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: Implications for a "bloodless" surgical technique. J Am Coll Surg 1997;184:618-629.
4. Sandiford FM, Chiariello L, Hallman GL, et al: Aortocoronary bypass in Jehovah's Witnesses: Report of 36 patients. J Thorac Cardiovasc Surg 1974;68:1-7.
5. Alghamdi AA, Davis A, Brister S, et al: Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion 2006;46(7):1120-1129. (Pubitemid 44139485)
6. Magovern JA, Sakert T, Magovern GJ, et al: A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol 1996,28(5):1147-1153. (Pubitemid 26376987)
7. Nilsson J, Algotsson L, Höglund P, et al: Comparison of 19 pre-operative risk stratification models in open heart surgery. Eur Heart J 2006,27:867-874.
8. Podestà A, Parodi E, Dottori V, et al: Epoetin alpha in elective coronary and valve surgery in Jehovah's Witnesses patients. Experience in 45 patients. Minerva Cardioangiol 2002;50(2):125-131.
9. Vaislic C, Bical O, Farge C, et al: Totally minimized extracorporeal circulation: An important benefit for coronary artery bypass grafting in Jehovah's witnesses. Heart Surg Forum 2003;6(5):307-310. (Pubitemid 37304572)
10. Stamou SC, White T, Barnett S, et al: Comparisons of cardiac surgery outcomes in Jehovah's versus non-Jehovah's Witnesses. Am J Cardiol 2006;98:1223-1225. (Pubitemid 44584111)
11. Juraszek A, Dziodzio T, Roedler S, et al: Results of open heart surgery in Jehovah's Witnesses patients. J Cardiovasc Surg (Torino) 2009;50(2):247-250.
12. Pompei E, Tursi V, Guzzi G, et al: Mid-term clinical outcomes in cardiac surgery of Jehovah's witnesses. J Cardiovasc Med (Hagerstown) 2010;11(3):170-174.
13. Bhaskar B, Jack RK, Mullany D, et al: Comparison of outcome in Jehovah's Witness patients in cardiac surgery: An Australian experience. Heart Lung Circ 2010;19(11):655-659.
14. El Azab SR, Vrakking R, Verhage G, et al: Safety of cardiac surgery without blood transfusion: A retrospective study in Jehovah's Witness patients. Anaesthesia. 2010;65(4):348-352.
15. Carson JL, Duff A, Poses RM, et al: Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348(9034):1055-1060. (Pubitemid 26343599)
16. DeFoe GR, Ross CS, Olmstead EM, et al: Northern New England Cardiovascular Disease Study Group. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Ann Thorac Surg 2001;71(3):769-776. (Pubitemid 32210372)
17. Reeves BC, Murphy GJ: Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery. Curr Opin Cardiol 2008;23(6):607-612.
18. Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-165.
19. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339: 584-590. (Pubitemid 28385655)
20. Singh AK: What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level. Curr Opin Nephrol Hypertens 2010;19(5):420-424.
21. Unger EF, Thompson AM, Blank MJ, et al: Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 2010; 362(3); 189-192.
22. Ranucci M, Pazzaglia A, Bianchini C, et al: Body size, gender, and transfusions as determinants of outcome after coronary operations. Ann Thorac Surg 2008;85(2):481-486. (Pubitemid 351147817)
23. Saczkowski R, Bernier PL, Tchervenkov CI, et al: Retrograde autologous priming and allogeneic blood transfusions: A meta-analysis. Interact Cardiovasc Thorac Surg 2009;8(3):373-376.
24. Hou X, Yang F, Liu R, et al: Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion in small adults: A prospective, randomized trial. Eur J Anaesthesiol 2009;26(12):1061-1066.
25. Saxena P, Saxena N, Jain A, et al: Intraoperative autologous blood donation and retrograde autologous priming for cardiopulmonary bypass: A safe and effective technique for blood conservation. Ann Card Anaesth 2003;6(1):47-51.
26. Sato K, Namura O, Hanzawa K, et al: Major factors of homologous blood transfusion in valvular heart operation with intraoperative autologous blood predonation in cases with difficulty in preoperative predonation. Int J Artif Organs 2010;33(2):72-75.
27. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al: Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: A meta-analysis. Circulation 1999;99(1):81-89. (Pubitemid 29035961)
28. Mangano DT, Tudor IC, Dietzel C: Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354(4):353-365.
29. Henry DA, Carless PA, Moxey AJ, et al: Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;17(4):CD001886.
30. Ozier Y, Bellamy L: Pharmacological agents: Antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol 2010;24(1):107-119.
31. Cattaneo M: The use of desmopressin in open-heart surgery. Haemophilia 2008;14(Suppl 1):40-47.
32. Sohn N, Marcoux J, Mycyk T, et al: The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion 2009;24(4):231-237.
33. Schulze CJ, Han L, Ghorpade N, et al: Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: A prospective randomized trial. J Card Surg 2009;24(4):363-368.
34. Rubens FD, Labow RS, Lavallée GR, et al: Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer. Ann Thorac Surg 1999;67(3):689-696.
35. Rubens FD, Nathan H, Labow R, et al: Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 2005;79(2):655-665. (Pubitemid 40186577)
36. Wang G, Bainbridge D, Martin J, et al: The efficacy of an intraoperative cell saver during cardiac surgery: A meta-analysis of randomized trials. Anesth Analg 2009;109(2):320-330.
37. Klein AA, Nashef SA, Sharples L, et al: A randomized controlled trial of cell salvage in routine cardiac surgery. Anesth Analg 2008;107(5):1487-1495.
38. Hashemzadeh K, Hashemzadeh S: In-hospital outcomes of delayed sternal closure after open cardiac surgery. J Card Surg 2009;24(1):30-33.
39. Shalabi RI, Amin M, Ayed AK, et al: Delayed sternal closure is a life saving decision. Ann Thorac Cardiovasc Surg 2002;8(4):220-223.